AYTU (Aytu BioPharma) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AYTU Aytu BioPharma Inc AYTU
40 GF Score
Price $2.20
GF Value $0.85
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Aytu BioPharma FFO per Share?

FFO per Share only applies to REITs.

AYTU
40GF Score
Aytu BioPharma Inc AYTU
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Aytu BioPharma (AYTU) Overvalued in 2026?

Based on GuruFocus' analysis, Aytu BioPharma stock appears to be overvalued. The current stock price of $2.20 is trading 158.8% above its estimated GF Value™ of $0.85. GuruFocus considers Aytu BioPharma to be Significantly Overvalued.

Key valuation signals for AYTU:

  • FFO per Share:
  • GF Value™: $0.85 vs. price of $2.20 (158.8% above fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the AYTU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aytu BioPharma Business Description

Address 7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
40GF Score

Get the complete analysis for AYTU

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.20
Price
$0.85
GF Value